JAK2 allele burden in the myeloproliferative neoplasms: Effects on phenotype, prognosis and change with treatment

Therapeutic Advances in Hematology

Volumn 2, Issue 1, 2011, Pages 21-32

  Vannucchi, Alessandro M ^a   Pieri, Lisa ^a   Guglielmelli, Paola ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

JAK2; mutations; myeloproliferative neoplasms; prognosis; therapy

Indexed keywords

EID: 84993730731     PISSN: 20406207     EISSN: 20406215     Source Type: Journal    
DOI: 10.1177/2040620710394474     Document Type: Review

References (106)

1. Abdel-Wahab O. Manshouri T. Patel J. Harris K. Yao J. Hedvat C. et al (2010) Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res 70: 447–452.
2. Akada H. Yan D. Zou H. Fiering S. Hutchison R.E. Mohi M.G. (2010) Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood 115: 3589–3597.
3. Alchalby, H., Badbaran, A., Zabelina, T., Kobbe, G., Hahn, J., Wolff, D. et al. (2010) Impact of JAK2V617F-mutation status, allele burden and clearance after allogeneic stem cell transplantation for myelofibrosis. Blood, in press.
4. Antonioli E. Guglielmelli P. Pancrazzi A. Bogani C. Verrucci M. Ponziani V. et al (2005) Clinical implications of the JAK2V617F mutation in essential thrombocythemia. Leukemia 19: 1847–1849.
5. Antonioli E. Guglielmelli P. Poli G. Bogani C. Pancrazzi A. Longo G. et al (2008) Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica 93: 41–48.
6. Barbui T. Carobbio A. Cervantes F. Vannucchi A.M. Guglielmelli P. Antonioli E. et al (2010) Thrombosis in primary myelofibrosis: incidence and risk factors. Blood 115: 778–782.
7. Barosi G. Bergamaschi G. Marchetti M. Vannucchi A.M. Guglielmelli P. Antonioli E. et al (2007) JAK2V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 110: 4030–4036.
8. Barosi G. Birgegard G. Finazzi G. Griesshammer M. Harrison C. Hasselbalch H.C. et al (2009) Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood 113: 4829–4833.
9. Baxter E.J. Scott L.M. Campbell P.J. East C. Fourouclas N. Swanton S. et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365: 1054–1061.
10. Beer P.A. Campbell P. Scott L.M. Bench A.J. Erber W.N. Bareford D. et al (2008) MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 112: 141–149.
11. Beer P.A. Delhommeau F. Le Couedic J.P. Dawson M.A. Chen E. Bareford D. et al (2010 a) Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood 115: 2891–2900.
12. Beer P.A. Ortmann C.A. Campbell P.J. Green A.R. (2010 b) Independently acquired biallelic JAK2 mutations are present in a minority of patients with essential thrombocythemia. Blood 116: 1013–1014.
13. Bellosillo B. Martinez-Aviles L. Gimeno E. Florensa L. Longaron R. Navarro G. et al (2007) A higher JAK2V617F-mutated clone is observed in platelets than in granulocytes from essential thrombocythemia patients, but not in patients with polycythemia vera and primary myelofibrosis. Leukemia 21: 1331–1332.
14. Benjamini O. Koren-Michowitz M. Amariglio N. Kroger N. Nagler A. Shimoni A. (2008) Relapse of postpolycythemia myelofibrosis after allogeneic stem cell transplantation in a polycythemic phase: successful treatment with donor lymphocyte infusion directed by quantitative PCR test for V617F-JAK2 mutation. Leukemia 22: 1961–1963.
15. Campbell P.J. Baxter E.J. Beer P.A. Scott L.M. Bench A.J. Huntly B.J. et al (2006 a) Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood 108: 3548–3555.
16. Campbell P.J. Griesshammer M. Dohner K. Dohner H. Kusec R. Hasselbalch H.C. et al (2006 b) V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood 107: 2098–2100.
17. Campbell P.J. Scott L.M. Buck G. Wheatley K. East C.L. Marsden J.T. et al (2005) Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2V617F mutation status: a prospective study. Lancet 366: 1945–1953.
18. Carbuccia N. Murati A. Trouplin V. Brecqueville M. Adelaide J. Rey J. et al (2009) Mutations of ASXL 1 gene in myeloproliferative neoplasms. Leukemia 23: 2183–2186.
19. Carobbio A. Finazzi G. Antonioli E. Guglielmelli P. Vannucchi A.M. Dellacasa C.M. et al (2009) JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera. Exp Hematol 37: 1016–1021.
20. Carobbio A. Finazzi G. Guerini V. Spinelli O. Delaini F. Marchioli R. et al (2007) Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and JAK2 mutation status. Blood 109: 2310–2313.
21. Cervantes F. Dupriez B. Pereira A. Passamonti F. Reilly J.T. Morra E. et al (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113: 2895–2901.
22. Chaligne R. James C. Tonetti C. Besancenot R. Le Couedic J.P. Fava F. et al (2007) Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis. Blood 110: 3735–3743.
23. Delhommeau F. Dupont S. Della Valle V. James C. Trannoy S. Masse A. et al (2009) Mutation in TET 2 in myeloid cancers. N Engl J Med 360: 2289–2301.
24. Delhommeau F. Dupont S. Tonetti C. Masse A. Godin I. Le Couedic J.P. et al (2007) Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. Blood 109: 71–77.
25. Dupont S. Masse A. James C. Teyssandier I. Lecluse Y. Larbret F. et al (2007) The JAK2V617F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood 110: 1013–1021.
26. Ernst, T., Chase, A.J., Score, J., Hidalgo-Curtis, C.E., Bryant, C., Jones, A.V. et al. (2010) Inactivating mutations of the histone methyltransferase gene EZH 2 in myeloid disorders. Nat Genet, in press.
27. Finazzi G. Barbui T. (2005) Risk-adapted therapy in essential thrombocythemia and polycythemia vera. Blood Rev 19: 243–252.
28. Girodon F. Schaeffer C. Cleyrat C. Mounier M. Lafont I. Dos Santos F. et al (2008) Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy. Haematologica 93: 1723–1727.
29. Goldman J.M. Green A.R. Holyoake T. Jamieson C. Mesa R. Mughal T. et al (2009) Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues. Leukemia 23: 1708–1715.
30. Grand F.H. Hidalgo-Curtis C.E. Ernst T. Zoi K. Zoi C. McGuire C. et al (2009) Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 113: 6182–6192.
31. Green A. Beer P. (2010) Somatic mutations of IDH 1 and IDH 2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med 362: 369–370.
32. Guerini V. Barbui V. Spinelli O. Salvi A. Dellacasa C. Carobbio A. et al (2008) The histone deacetylase inhibitor ITF 2357 selectively targets cells bearing mutated JAK2(V617F). Leukemia 22: 740–747.
33. Guglielmelli P. Barosi G. Pieri L. Antonioli E. Bosi A. Vannucchi A.M. (2009 a) JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis. Haematologica 94: 144–146.
34. Guglielmelli P. Barosi G. Specchia G. Rambaldi A. Lo Coco F. Antonioli E. et al (2009 b) Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood 114: 1477–1483.
35. Guglielmelli P. Pancrazzi A. Bergamaschi G. Rosti V. Villani L. Antonioli E. et al (2007) Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. Br J Haematol 137: 244–247.
36. Guglielmelli P. Tozzi L. Bogani C. Bartalucci N. Salati S. Manfredini R. et al (2008) Dysregulated expression of microRNA-16 contributes to abnormal erythropoiesis in patients with polycythemia vera. Blood 112: 199A–199A.
37. Hookham M.B. Elliott J. Suessmuth Y. Staerk J. Ward A.C. Vainchenker W. et al (2007) The myeloproliferative disorder-associated JAK2V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. Blood 109: 4924–4929.
38. Hussein K. Bock O. Theophile K. von Neuhoff N. Buhr T. Schlue J. et al (2009) JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis. Exp Hematol 37: 1186–1193, e1187.
39. Jager R. Gisslinger H. Passamonti F. Rumi E. Berg T. Gisslinger B. et al (2010) Deletions of the transcription factor Ikaros in myeloproliferative neoplasms. Leukemia 24: 1290–1298.
40. James C. Ugo V. Le Couedic J.P. Staerk J. Delhommeau F. Lacout C. et al (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434: 1144–1148.
41. Jones A.V. Silver R.T. Waghorn K. Curtis C. Kreil S. Zoi K. et al (2006) Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood 107: 3339–3341.
42. Kiladjian J.J. Cassinat B. Chevret S. Turlure P. Cambier N. Roussel M. et al (2008) Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 112: 3065–3072.
43. Kiladjian J.J. Masse A. Cassinat B. Mokrani H. Teyssandier I. Le Couedic J.P. et al (2010) Clonal analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2(V617F) clones without affecting TET 2 mutant cells. Leukemia 24: 1519–1523.
44. Kralovics R. (2008) Genetic complexity of myeloproliferative neoplasms. Leukemia 22: 1841–1848.
45. Kralovics R. Guan Y. Prchal J.T. (2002) Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp Hematol 30: 229–236.
46. Kralovics R. Passamonti F. Buser A.S. Teo S.S. Tiedt R. Passweg J.R. et al (2005 a) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352: 1779–1790.
47. Kralovics R. Teo S.S. Buser A.S. Brutsche M. Tiedt R. Tichelli A. et al (2005 b) Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood 106: 3374–3376.
48. Kralovics R. Teo S.S. Li S. Theocharides A. Buser A.S. Tichelli A. et al (2006) Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood 108: 1377–1380.
49. Kroger N. Alchalby H. Klyuchnikov E. Badbaran A. Hildebrandt Y. Ayuk F. et al (2009 a) JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation. Blood 113: 1866–1868.
50. Kroger N. Holler E. Kobbe G. Bornhauser M. Schwerdtfeger R. Baurmann H. et al (2009 b) Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 114: 5264–5270.
51. Lacout C. Pisani D.F. Tulliez M. Gachelin F.M. Vainchenker W. Villeval J.L. (2006) JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 108: 1652–1660.
52. Lambert, J.R., Everington, T., Linch, D.C. and Gale, R.E. (2009) In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm. Blood, in press.
53. Lasho T.L. Pardanani A. McClure R.F. Mesa R.A. Levine R.L. Gilliland D.G. et al (2006) Concurrent MPL 515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time. Br J Haematol 135: 683–687.
54. Lasho T.L. Pardanani A. Tefferi A. (2010) LNK mutations in JAK2 mutation-negative erythrocytosis. N Engl J Med 363: 1189–1190.
55. Levine R.L. Belisle C. Wadleigh M. Zahrieh D. Lee S. Chagnon P. et al (2006) X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood 107: 4139–4141.
56. Levine R.L. Pardanani A. Tefferi A. Gilliland D.G. (2007) Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 7: 673–683.
57. Levine R.L. Wadleigh M. Cools J. Ebert B.L. Wernig G. Huntly B.J. et al (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7: 387–397.
58. Li, J., Spensberger, D., Ahn, J.S., Anand, S., Beer, P.A., Ghevaert, C. et al. (2010) JAK2V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2V617F-positive essential thrombocythemia. Blood, in press.
59. Lippert E. Girodon F. Hammond E. Jelinek J. Reading N.S. Fehse B. et al (2008) Concordance of assays designed for the quantification of JAK2V617F: a multicenter study. Haematologica 94: 38–45.
60. Marty C. Lacout C. Martin A. Hasan S. Jacquot S. Birling M.C. et al (2010) Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice. Blood 116: 783–787.
61. Mesa, R.A., Green, A., Barosi, G., Verstovsek, S., Vardiman, J. and Gale, R.P. (2010) MPN-associated myelofibrosis (MPN-MF). Leuk Res, in press.
62. Nussenzveig R.H. Swierczek S.I. Jelinek J. Gaikwad A. Liu E. Verstovsek S. et al (2007) Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol 35: 32–38.
63. Oh S.T. Simonds E.F. Jones C. Hale M.B. Goltsev Y. Gibbs K.D. Jr et al (2010) Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 116: 988–992.
64. Olcaydu D. Harutyunyan A. Jager R. Berg T. Gisslinger B. Pabinger I. et al (2009) A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet 41: 450–454.
65. Pardanani A. (2008) JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia 22: 23–30.
66. Pardanani A.D. Levine R.L. Lasho T. Pikman Y. Mesa R.A. Wadleigh M. et al (2006) MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 108: 3472–3476.
67. Passamonti F. Cervantes F. Vannucchi A.M. Morra E. Rumi E. Pereira A. et al (2010 a) A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 115: 1703–1708.
68. Passamonti F. Rumi E. Pietra D. Della Porta M.G. Boveri E. Pascutto C. et al (2006) Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood 107: 3676–3682.
69. Passamonti, F., Rumi, E., Pietra, D., Elena, C., Boveri, E., Arcaini, L. et al. (2010 b) A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia, in press.
70. Pikman Y. Lee B.H. Mercher T. McDowell E. Ebert B.L. Gozo M. et al (2006) MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 3: e270–e270.
71. Quintas-Cardama A. Kantarjian H. Manshouri T. Luthra R. Estrov Z. Pierce S. et al (2009) Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 27: 5418–5424.
72. Rambaldi A. Dellacasa C.M. Finazzi G. Carobbio A. Ferrari M.L. Guglielmelli P. et al (2010) A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol 150: 446–455.
73. Ricksten A. Palmqvist L. Johansson P. Andreasson B. (2008) Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia. Haematologica 93: 1260–1261.
74. Rinaldi C.R. Rinaldi P. Gemei M. Grimaldi F. Battipaglia G. Del Vecchio L. et al (2010) JAK2V617F mutation persists in blasts and mature cells of transformed JAK2V617F-positive-myeloproliferative neoplasia: a European Leukemia Net (ENL) study. Am J Hematol 85: 383–386.
75. Scott L.M. Scott M.A. Campbell P.J. Green A.R. (2006) Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood 108: 2435–2437.
76. Scott L.M. Tong W. Levine R.L. Scott M.A. Beer P.A. Stratton M.R. et al (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356: 459–468.
77. Shide K. Shimoda H.K. Kumano T. Karube K. Kameda T. Takenaka K. et al (2008) Development of ET, primary myelofibrosis and PV in mice expressing JAK2V617F. Leukemia 22: 87–95.
78. Silver, R.T., Vandris, K., Wang, Y.L., Adriano, F., Jones, A.V., Christos, P.J. et al. (2010) JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy. Leuk Res, in press.
79. Sirhan S. Lasho T.L. Hanson C.A. Mesa R.A. Pardanani A. Tefferi A. (2008) The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea. Am J Hematol 83: 363–365.
80. Spivak J.L. (2002) Polycythemia vera: myths, mechanisms, and management. Blood 100: 4272–4290.
81. Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., et al. (2008) WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. Lyon: International Agency for Research on Cancer.
82. Tefferi A. (2010) Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 24: 1128–1138.
83. Tefferi A. Lasho T.L. Abdel-Wahab O. Guglielmelli P. Patel J. Caramazza D. et al (2010) IDH 1 and IDH 2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 24: 1302–1309.
84. Tefferi A. Lasho T.L. Huang J. Finke C. Mesa R.A. Li C.Y. et al (2008) Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 22: 756–761.
85. Tefferi A. Lasho T.L. Schwager S.M. Steensma D.P. Mesa R.A. Li C.Y. et al (2005) The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. Br J Haematol 131: 320–328.
86. Tefferi A. Lasho T.L. Schwager S.M. Strand J.S. Elliott M. Mesa R. et al (2006) The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer 106: 631–635.
87. Tefferi A. Thiele J. Orazi A. Kvasnicka H.M. Barbui T. Hanson C.A. et al (2007) Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 110: 1092–1097.
88. Theocharides A. Boissinot M. Girodon F. Garand R. Teo S.S. Lippert E. et al (2007) Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 110: 375–379.
89. Theocharides A. Passweg J.R. Medinger M. Looser R. Li S. Hao-Shen H. et al (2008) The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders. Haematologica 93: 1890–1893.
90. Tiedt R. Hao-Shen H. Sobas M.A. Looser R. Dirnhofer S. Schwaller J. et al (2008) Ratio of mutant JAK2-V617F to wild-type JAK2 determines the MPD phenotypes in transgenic mice. Blood 111: 3931–3940.
91. Vannucchi A.M. (2010) From palliation to targeted therapy in myelofibrosis. N Engl J Med 363: 1180–1182.
92. Vannucchi A.M. Antonioli E. Guglielmelli P. Longo G. Pancrazzi A. Ponziani V. et al (2007 a) Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 21: 1952–1959.
93. Vannucchi A.M. Antonioli E. Guglielmelli P. Pancrazzi A. Guerini V. Barosi G. et al (2008 a) Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood 112: 844–847.
94. Vannucchi A.M. Antonioli E. Guglielmelli P. Pardanani A. Tefferi A. (2008 b) Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 22: 1299–1307.
95. Vannucchi A.M. Antonioli E. Guglielmelli P. Rambaldi A. Barosi G. Marchioli R. et al (2007 b) Clinical profile of homozygous JAK2V617F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 110: 840–846.
96. Vannucchi A.M. Antonioli E. Pancrazzi A. Guglielmelli P. Di Lollo S. Alterini R. et al (2007 c) The clinical phenotype of patients with essential thrombocythemia harboring MPL W515l/K mutation. Blood 110: 678A–678A.
97. Vannucchi A.M. Guglielmelli P. (2008) Molecular pathophysiology of Philadelphia-negative myeloproliferative disorders: beyond JAK2 and MPL mutations. Haematologica 93: 972–976.
98. Vannucchi A.M. Guglielmelli P. Antonioli E. Mappa S. Pancrazzi A. Bogani C. et al (2006) Inconsistencies in the association between the JAK2(V617F) mutation and PRV-1 over-expression among the chronic myeloproliferative diseases. Br J Haematol 132: 652–654.
99. Vannucchi A.M. Guglielmelli P. Rambaldi A. Bogani C. Barbui T. (2009 a) Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives. J Cell Mol Med 13: 1437–1450.
100. Vannucchi A.M. Guglielmelli P. Tefferi A. (2009 b) Advances in understanding and management of myeloproliferative neoplasms. AC–A Cancer Journal for Clinicians 59: 171–191.
101. Verstovsek S. (2010) Therapeutic potential of Janus-activated kinase-2 inhibitors for the management of myelofibrosis. Clin Cancer Res 16: 1988–1996.
102. Verstovsek S. Kantarjian H. Mesa R.A. Pardanani A.D. Cortes-Franco J. Thomas D.A. et al (2010) Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363: 1117–1127.
103. Wernig G. Mercher T. Okabe R. Levine R.L. Lee B.H. Gilliland D.G. (2006) Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 107: 4274–4281.
104. Wolanskyj A.P. Lasho T.L. Schwager S.M. McClure R.F. Wadleigh M. Lee S.J. et al (2005) JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol 131: 208–213.
105. Xing S. Ho W.T. Zhao W. Ma J. Wang S. Xu X. et al (2008) Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood 111: 5109–5117.
106. Zaleskas V.M. Krause D.S. Lazarides K. Patel N. Hu Y. Li S. et al (2006) Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2V617F. PloS ONE 1: e18–e18.